MX2009011294A - Combinacion de farmacos y su uso en el tratamiento de la perdida muscular. - Google Patents

Combinacion de farmacos y su uso en el tratamiento de la perdida muscular.

Info

Publication number
MX2009011294A
MX2009011294A MX2009011294A MX2009011294A MX2009011294A MX 2009011294 A MX2009011294 A MX 2009011294A MX 2009011294 A MX2009011294 A MX 2009011294A MX 2009011294 A MX2009011294 A MX 2009011294A MX 2009011294 A MX2009011294 A MX 2009011294A
Authority
MX
Mexico
Prior art keywords
treatment
muscle loss
drug combination
prevention
present
Prior art date
Application number
MX2009011294A
Other languages
English (en)
Spanish (es)
Inventor
Julian Clive Gilbert
Robert William Gristwood
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707930A external-priority patent/GB0707930D0/en
Priority claimed from GB0707931A external-priority patent/GB0707931D0/en
Priority claimed from GB0710101A external-priority patent/GB0710101D0/en
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of MX2009011294A publication Critical patent/MX2009011294A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
MX2009011294A 2007-04-24 2008-04-24 Combinacion de farmacos y su uso en el tratamiento de la perdida muscular. MX2009011294A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0707930A GB0707930D0 (en) 2007-04-24 2007-04-24 New therapeutic use
GB0707931A GB0707931D0 (en) 2007-04-24 2007-04-24 New Therapeutic use
GB0710101A GB0710101D0 (en) 2007-05-25 2007-05-25 New Therapeutic use
PCT/GB2008/001452 WO2008129308A2 (en) 2007-04-24 2008-04-24 Drug combination and its use in the treatment of muscle loss

Publications (1)

Publication Number Publication Date
MX2009011294A true MX2009011294A (es) 2010-01-29

Family

ID=39639100

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011294A MX2009011294A (es) 2007-04-24 2008-04-24 Combinacion de farmacos y su uso en el tratamiento de la perdida muscular.

Country Status (16)

Country Link
US (1) US8653052B2 (enExample)
EP (1) EP2155180B1 (enExample)
JP (1) JP5627452B2 (enExample)
KR (1) KR101546977B1 (enExample)
CN (2) CN101730547A (enExample)
AU (1) AU2008240379B2 (enExample)
BR (1) BRPI0810461A2 (enExample)
CA (1) CA2721739C (enExample)
DK (1) DK2155180T3 (enExample)
EA (1) EA018918B1 (enExample)
ES (1) ES2592289T3 (enExample)
HK (1) HK1202262A1 (enExample)
IL (1) IL201426A (enExample)
MX (1) MX2009011294A (enExample)
NZ (1) NZ580975A (enExample)
WO (1) WO2008129308A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7417038B1 (en) 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
CA2615173C (en) 2005-07-14 2012-01-03 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
UA111822C2 (uk) 2010-11-24 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Новамедіка" Монотерапевтичий препарат селективного ліпофільного бета-агоніста тривалої дії і спосіб косметичного лікування ожиріння і контурного випинання
RU2695649C2 (ru) * 2014-08-05 2019-07-25 Раквалиа Фарма Инк. Производные серина в качестве агонистов грелиновых рецепторов
IL294709B2 (en) * 2020-01-13 2023-07-01 Astromedical Biotechnology Ltd Use of ketamine in the treatment of cachexia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3855801T2 (de) 1987-09-15 1997-07-03 Rowett Research Inst Anwendungsgebiete von beta-adrenergenen Agonisten
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
EP1494649B1 (en) * 2002-04-12 2012-01-04 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
ES2245612B1 (es) 2004-06-29 2007-08-16 Universidad De Barcelona Nuevo uso terapeutico del formoterol.
JP2009526087A (ja) * 2005-12-22 2009-07-16 アナボレックス, インコーポレイテッド 悪液質の予防および処置のための組成物および方法
US7947579B2 (en) 2006-02-13 2011-05-24 Stc.Unm Method of making dense, conformal, ultra-thin cap layers for nanoporous low-k ILD by plasma assisted atomic layer deposition

Also Published As

Publication number Publication date
CA2721739C (en) 2016-08-23
US20100130456A1 (en) 2010-05-27
AU2008240379B2 (en) 2012-10-04
US8653052B2 (en) 2014-02-18
EA018918B1 (ru) 2013-11-29
AU2008240379A1 (en) 2008-10-30
WO2008129308A2 (en) 2008-10-30
HK1202262A1 (en) 2015-09-25
CN104306381A (zh) 2015-01-28
CA2721739A1 (en) 2008-10-30
DK2155180T3 (en) 2016-09-12
IL201426A0 (en) 2010-05-31
BRPI0810461A2 (pt) 2014-10-14
JP2010525044A (ja) 2010-07-22
NZ580975A (en) 2012-10-26
EP2155180A2 (en) 2010-02-24
EA200970957A1 (ru) 2010-04-30
IL201426A (en) 2016-09-29
ES2592289T3 (es) 2016-11-29
EP2155180B1 (en) 2016-07-13
CN101730547A (zh) 2010-06-09
JP5627452B2 (ja) 2014-11-19
KR101546977B1 (ko) 2015-08-24
WO2008129308A3 (en) 2009-12-17
KR20100017205A (ko) 2010-02-16

Similar Documents

Publication Publication Date Title
IL249165A0 (en) Use of an antigen-mhc complex to prepare drugs for the prevention and treatment of autoimmune conditions
IL211907A (en) A herbal formulation containing a combination of plants, an anticancer preparation containing the formulation and the use of a formulation to prepare a drug for the treatment and / or prevention of cancer
EP1991218A4 (en) USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
WO2012154679A8 (en) Tricyclic pyrazole sulfonamide compounds and methods of making and using same
TW200637522A (en) Skin treatment articles and methods
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
SG171625A1 (en) Antiseptic-containing silicone elastomers
SI2176252T1 (sl) 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2009141541A3 (fr) Utilisation d' inhibiteurs de kif13a et d ' ap-1 pour inhiber la melanogenese
MX2009011294A (es) Combinacion de farmacos y su uso en el tratamiento de la perdida muscular.
ZA201003037B (en) Use of 3, 11b-cis-dihydrotettabenazine in the treatment of multiple sclerosis and autoimmune myelitis
WO2009073612A3 (en) Homeopathic remedies for use before and after aesthetic injectable and surgical procedures to minimize swelling and bruising
WO2008094054A3 (en) 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
SI1861080T1 (sl) Idebenon za zdravljenje miĺ iäśnih distrofij, njegovo pripravo in farmacevtska uporaba
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
WO2008157365A3 (en) Vinylazacycloalkanes for treating neuropathic pain
WO2010048384A3 (en) Arformoterol and tiotropium compositions and methods for use
WO2006128847A3 (en) Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
ZA201005398B (en) 15,16-methylene-17-(1'-propenyl)-17,3'-oxidoestra-4-en-3-one derivative,use thereof,and medicament containing said derivative
WO2007115997A3 (de) Kombinationspräparate aus modafinil, ritalin und topiramat bei kokainabhängigkeit und/oder zur behandlung von impulskontrollstörungen
MY150436A (en) 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
WO2009140649A8 (en) Rab3b for the treatment and prevention of parkinson's disease
WO2008061966A3 (en) New use of flibanserin

Legal Events

Date Code Title Description
FG Grant or registration